Cargando…
The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446508/ https://www.ncbi.nlm.nih.gov/pubmed/34539673 http://dx.doi.org/10.3389/fimmu.2021.737083 |
_version_ | 1784568893589684224 |
---|---|
author | Tejedor Vaquero, Sonia de Campos-Mata, Leire Ramada, José María Díaz, Pilar Navarro-Barriuso, Juan Ribas-Llaurado, Clara Rodrigo Melero, Natalia Carolis, Carlo Cerutti, Andrea Gimeno, Ramon Magri, Giuliana |
author_facet | Tejedor Vaquero, Sonia de Campos-Mata, Leire Ramada, José María Díaz, Pilar Navarro-Barriuso, Juan Ribas-Llaurado, Clara Rodrigo Melero, Natalia Carolis, Carlo Cerutti, Andrea Gimeno, Ramon Magri, Giuliana |
author_sort | Tejedor Vaquero, Sonia |
collection | PubMed |
description | mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we characterized serum antibody classes and subclasses targeting the spike receptor-binding domain of SARS-CoV-2 wild type and α, β, γ and δ variants in a longitudinal cohort of SARS-CoV-2 naïve and COVID-19 recovered individuals receiving the mRNA-1273 vaccine. We found that mRNA-1273 vaccine recipients developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by natural infection. Importantly, these antibody responses targeted both wild type SARS-CoV-2 as well as its α, β, γ and δ variants. Following primary vaccination, individuals with pre-existing immunity showed higher induction of all antibodies but IgG3 compared to SARS-CoV-2-naïve subjects. Unlike naïve individuals, COVID-19 recovered subjects did not mount a recall antibody response upon the second vaccine dose. In these individuals, secondary immunization resulted in a slight reduction of IgG1 against the receptor-binding domain of β and γ variants. Despite the lack of recall humoral response, vaccinees with pre-existing immunity still showed higher titers of IgG1 and IgA to all variants analyzed compared to fully vaccinated naïve individuals. Our findings indicate that mRNA-1273 vaccine triggered cross-variant antibody responses with distinct profiles in vaccinees with or without pre-existing immunity and suggest that individuals with prior history of SARS-CoV-2 infection may not benefit from the second mRNA vaccine dose with the current standard regimen. |
format | Online Article Text |
id | pubmed-8446508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84465082021-09-18 The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity Tejedor Vaquero, Sonia de Campos-Mata, Leire Ramada, José María Díaz, Pilar Navarro-Barriuso, Juan Ribas-Llaurado, Clara Rodrigo Melero, Natalia Carolis, Carlo Cerutti, Andrea Gimeno, Ramon Magri, Giuliana Front Immunol Immunology mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we characterized serum antibody classes and subclasses targeting the spike receptor-binding domain of SARS-CoV-2 wild type and α, β, γ and δ variants in a longitudinal cohort of SARS-CoV-2 naïve and COVID-19 recovered individuals receiving the mRNA-1273 vaccine. We found that mRNA-1273 vaccine recipients developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by natural infection. Importantly, these antibody responses targeted both wild type SARS-CoV-2 as well as its α, β, γ and δ variants. Following primary vaccination, individuals with pre-existing immunity showed higher induction of all antibodies but IgG3 compared to SARS-CoV-2-naïve subjects. Unlike naïve individuals, COVID-19 recovered subjects did not mount a recall antibody response upon the second vaccine dose. In these individuals, secondary immunization resulted in a slight reduction of IgG1 against the receptor-binding domain of β and γ variants. Despite the lack of recall humoral response, vaccinees with pre-existing immunity still showed higher titers of IgG1 and IgA to all variants analyzed compared to fully vaccinated naïve individuals. Our findings indicate that mRNA-1273 vaccine triggered cross-variant antibody responses with distinct profiles in vaccinees with or without pre-existing immunity and suggest that individuals with prior history of SARS-CoV-2 infection may not benefit from the second mRNA vaccine dose with the current standard regimen. Frontiers Media S.A. 2021-09-03 /pmc/articles/PMC8446508/ /pubmed/34539673 http://dx.doi.org/10.3389/fimmu.2021.737083 Text en Copyright © 2021 Tejedor Vaquero, de Campos-Mata, Ramada, Díaz, Navarro-Barriuso, Ribas-Llaurado, Rodrigo Melero, Carolis, Cerutti, Gimeno and Magri https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Tejedor Vaquero, Sonia de Campos-Mata, Leire Ramada, José María Díaz, Pilar Navarro-Barriuso, Juan Ribas-Llaurado, Clara Rodrigo Melero, Natalia Carolis, Carlo Cerutti, Andrea Gimeno, Ramon Magri, Giuliana The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity |
title | The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity |
title_full | The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity |
title_fullStr | The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity |
title_full_unstemmed | The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity |
title_short | The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity |
title_sort | mrna-1273 vaccine induces cross-variant antibody responses to sars-cov-2 with distinct profiles in individuals with or without pre-existing immunity |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446508/ https://www.ncbi.nlm.nih.gov/pubmed/34539673 http://dx.doi.org/10.3389/fimmu.2021.737083 |
work_keys_str_mv | AT tejedorvaquerosonia themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT decamposmataleire themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ramadajosemaria themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT diazpilar themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT navarrobarriusojuan themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ribasllauradoclara themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT rodrigomeleronatalia themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT caroliscarlo themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ceruttiandrea themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT gimenoramon themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT magrigiuliana themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT tejedorvaquerosonia mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT decamposmataleire mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ramadajosemaria mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT diazpilar mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT navarrobarriusojuan mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ribasllauradoclara mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT rodrigomeleronatalia mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT caroliscarlo mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ceruttiandrea mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT gimenoramon mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT magrigiuliana mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity |